Computational Screening of Vitex negundo Compounds for Potential Arthritis Therapies in India

Year : 2024 | Volume : 13 | Issue : 01 | Page : 01 18
    By

    Ramayanam Navakanth Raju,

  1. Assistant Professor, Department of Pharmacy, MB School of Pharmaceutical Sciences, Tirupati, Andhra Pradesh, India

Abstract

Objective: Arthritis is a pervasive medical condition that manifests as inflammation and discomfort within the joints. As of September 2021, arthritis has affected an estimated 180 million people in India, making it a substantial public health concern with a considerable impact on individuals’ quality of life and healthcare systems. Therefore, using molecular docking, drug-likeness prediction, and ADME analysis, an effort was made to identify natural compounds from Vitex negundo, which have many medicinal properties in Indian Ayurveda, to avoid this condition. Methodology: A computational approach was employed to evaluate the inhibitory potential of several phytochemicals on the target proteins, 1G0Y (IL-1), 1Alu (IL-6), and 5vqp (TFG-B), which were sourced from the PDB database. Docking was carried out systematically using IMPAAT, PubChem, PDB, Open Bable, BIOVIA Discovery Studio Visualizer, PDB sum generate, PyRx, and ADMETlab 2.0 after the removal of the ligands with weak binding and compounds that can disrupt docking. Results: The results of the docking analysis showed that the selected ligands possessed improved binding affinities for each of the three target proteins. The statistical distribution of protein combinations with backbone dihedral angles is shown by a Ramachandran plot. Three compounds from Vitex negundo were identified through molecular docking studies as having a potential binding affinity to provide anti-inflammatory effects. All three compounds were found to be safe and to have drug-like qualities according to the ADMET profile and drug-likeness prediction. Conclusion: This computer study examined how Vitex negundo compounds can be used to treat arthritis in India. Our comprehensive molecular docking, drug similarity prediction, and ADME analyses showed that these drugs bound strongly to arthritic target proteins. Lutein and beta-sitosterin showed promising anti-inflammatory properties, bringing hope for arthritis therapies and enhanced quality of life while relieving India’s healthcare system

Keywords: Arthritis, Vitex negundo, 1G0Y(IL-1), 1Alu (IL-6), and 5vqp (TFG B), luteolin, beta-sitosterin, elixene, molecular docking, ADMET.

[This article belongs to Research & Reviews : Journal of Computational Biology ]

How to cite this article:
Ramayanam Navakanth Raju. Computational Screening of Vitex negundo Compounds for Potential Arthritis Therapies in India. Research & Reviews : Journal of Computational Biology. 2024; 13(01):01-18.
How to cite this URL:
Ramayanam Navakanth Raju. Computational Screening of Vitex negundo Compounds for Potential Arthritis Therapies in India. Research & Reviews : Journal of Computational Biology. 2024; 13(01):01-18. Available from: https://journals.stmjournals.com/rrjocb/article=2024/view=150390


Browse Figures

References

  1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmunity Rev. 2005;4(3):130–6. DOI: 10.1016/j.autrev.2004.09.002. PubMed: 15823498.
  2. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–38. DOI: 10.1016/S0140-6736(16)30173-8. PubMed: 27156434.
  3. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423:356–61. DOI: 10.1038/nature01661. PubMed: 12748655.
  4. Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T, Williams B, Gabriel S, Lassere M, Johns N, Buchbinder R, Woolf A, March L. The global burden of rheumatoid arthritis: Estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1316–22. DOI: 10.1136/annrheumdis-2013-204627. PubMed: 24550173.
  5. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365:2205–19. DOI: 10.1056/NEJMra1004965. PubMed: 22150039.
  6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7:429–42. DOI: 10.1038/nri2094. PubMed: 17525752.
  7. van Vollenhoven RF. Treatment of rheumatoid arthritis: State of the art 2009. Nat Rev Rheumatol. 2009;5:531–41. DOI: 10.1038/nrrheum.2009.182. PubMed: 19798027.
  8. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med. 2001;344:907–16. DOI: 10.1056/NEJM200103223441207. PubMed: 11259725.
  9. Kalliolias GD, Ivashkiv LB. Overview of the biology of type I interferons. Arthritis Res Ther. 2010;12(Suppl 1). DOI: 10.1186/ar2881. PubMed: 20392288.
  10. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med. 2006;355:704–12. DOI: 10.1056/NEJMct055183. PubMed: 16914706.
  11. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol. 2001;19:163–96. DOI: 10.1146/annurev.immunol.19.1.163. PubMed: 11244034.
  12. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537–45. DOI: 10.1172/JCI36389. PubMed: 18982160.
  13. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002;4(Suppl 3):S265–S272. DOI: 10.1186/ar578. PubMed: 12110146.
  14. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot EE, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O’Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68:1–26. DOI: 10.1002/art.39480. PubMed: 26545940.
  15. Singh D, Aggarwal A. Role of tumor necrosis factor inhibitors in rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord. 2019;12:1179544119835883. DOI: 10.1177/1179544119835883.
  16. McInnes IB, Schett G. The Pathogenesis of Rheumatoid Arthritis. N Engl J Med. 2011;365:2205–19. DOI: 10.1056/NEJMra1004965.
  17. Scally SW, Law SC, Ting YT, Heemst JV, Sokolove J, Deutsch AJ, Bridie Clemens E, Moustakas AK, Papadopoulos GK, van der Woude D, Smolik I, Hitchon CA, Robinson DB, Ferucci ED, Bernstein CN, Meng X, Anaparti V, Huizinga T, Kedzierska K, Reid HH, Raychaudhuri S, Toes RE, Rossjohn J, El-Gabalawy H, Thomas R. Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis. Ann Rheum Dis. 2017;76:1915–23. DOI: 10.1136/annrheumdis-2017-211300. PubMed: 28801345.
  18. Henderson J, O’Reilly S. Inflammasome lights up in systemic sclerosis. Arthritis Res Ther. 2017;19:205. DOI: 10.1186/s13075-017-1420-z. PubMed: 28923085.
  19. Mao H, Chen M, Su Y, Wu N, Yuan M, Yuan S, Brestic M, Zivcak M, Zhang H, Chen Y. Comparison on Photosynthesis and Antioxidant Defense Systems in Wheat with Different Ploidy Levels and Octoploid Triticale. Int J Mol Sci. 2018;19. DOI: 10.3390/ijms19103006. PubMed: 30279334.
  20. Scanzello CR, Goldring SR. The role of synovitis in osteoarthritis pathogenesis. Bone. 2012;51:249–57. DOI: 10.1016/j.bone.2012.02.012. PubMed: 22387238.
  21. van Laar JM, van der Woude D. Role of TGF-β signaling in control of T-cell–mediated inflammation in rheumatoid arthritis. F1000Res. 2017;6:625. DOI: 10.12688/f1000research.10540.1.
  22. Conaghan PG, Cook AD, Hamilton JA, Tak PP, Bridges SL Jr. Pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2018;14:627–41. DOI: 10.1038/s41584-018-0073-0.
  23. Arend WP, Firestein GS. Pre-rheumatoid arthritis: Predisposition and transition to clinical synovitis. Nat Rev Rheumatol. 2012;8(10):573–86. DOI: 10.1038/nrrheum.2012.134. PubMed: 22907289.
  24. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213:626–34. DOI: 10.1002/jcp.21258. PubMed: 17786965.
  25. Inglis JJ, McNamee KE. Cytokines in rheumatoid arthritis. Inflamm Regen. 2009;29:250–6. DOI: 10.2492/inflammregen.29.250.
  26. Li J, Hsu HC, Mountz JD. Managing macrophages in rheumatoid arthritis by reform or removal. Curr Rheumatol Rep. 2012;14:445–54. DOI: 10.1007/s11926-012-0272-4. PubMed: 22855296.
  27. Kinne RW, Stuhlmüller B, Burmester GR. Cells of the synovium in rheumatoid arthritis. Macrophages. Arthritis Res Ther. 2007;9:224. DOI: 10.1186/ar2333. PubMed: 18177511.
  28. Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, Renduchintala K, Zhu J, Bricel S, Silka K, Bach D, Heur M, Christianakis S, Arkfeld DG, Irvine J, Mack WJ, Stohl W. Tear cathepsin S as a candidate biomarker for Sjögren’s syndrome. Arthritis Rheumatol. 2014;66:1872–81. DOI: 10.1002/art.38633. PubMed: 24644101.
  29. Miceli-Richard C, Gottenberg JE, Mariette X. CTLA-4 polymorphism and primary Sjögren’s syndrome: Authors’ response. Arthritis Res Ther. 2007;9. DOI: 10.1186/ar2199.
  30. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1977;146:857–68. DOI: 10.1084/jem.146.3.857. PubMed: 894190.
  31. Klareskog L, Lundberg K, Malmström V. Autoimmunity in rheumatoid arthritis: Citrulline immunity and beyond. Adv Immunol. 2013;118:129–58. DOI: 10.1016/B978-0-12-407708-9.00003-0. PubMed: 23683943.
  32. Zhang Z, Xing X, Hensley G, Chang LW, Liao W, Abu-Amer Y, Sandell LJ. Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization. Arthritis Rheum. 2010;62:1993–2003. DOI: 10.1002/art.27473.
  33. Ermoza K, Glatigny S, Jah N, Camilo V, Mambu Mambueni H, Araujo LM, Chiocchia G, Breban M. Tolerogenic XCR1+ dendritic cell population is dysregulated in HLA-B27 transgenic rat model of spondyloarthritis. Arthritis Res Ther. 2019;21:46. DOI: 10.1186/s13075-019-1827-9. PubMed: 30717755.
  34. Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin. 2007;45:27–37. DOI: 10.1097/AIA.0b013e318034194e. PubMed: 17426506.
  35. Schett G, Neurath MF. Resolution of chronic inflammatory disease: Universal and tissue-specific concepts. Nat Commun. 2018;9:3261. DOI: 10.1038/s41467-018-05800-6. PubMed: 30111884.
  36. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017;389(10086):2338–48. DOI: 10.1016/S0140-6736(17)31491-5. PubMed: 28612748.
Regular Issue Subscription Original Research
Volume 13
Issue 01
Received 27/03/2024
Accepted 15/04/2024
Published 22/04/2024
425

Login


My IP

PlumX Metrics